That is real strength and determination to counter the drawback. Pranam KR IRS 20326
On Fri, 20 Mar 2026 at 05:56, APS Mani <[email protected]> wrote: > I am glad that under the 'reference' most are Japanese. In Japan, they > have a systematic schedule to get rid of diabetes. I tried there for four > decades but did not succeed. Back in my village for more than a decade > now, I have been free from insulin injection for the last three months. A > humble effort on diet, routine stretching, and simple exercises fitting to > my present age. Happy, Mani > > On Thu, Mar 19, 2026 at 1:57 PM Rajaram Krishnamurthy < > [email protected]> wrote: > >> A new peptide-based drug-delivery strategy may bring scientists closer to >> an oral form of insulin. >> >> For more than 100 years, scientists have pursued the idea of delivering >> insulin as a pill. This goal has remained difficult to achieve because >> insulin breaks down in the digestive system and the intestine lacks a >> natural transport pathway that allows the hormone to enter the bloodstream. >> >> Because of these biological barriers, many people with diabetes still >> depend on daily insulin injections, which can place a significant burden on >> long-term treatment and quality of life. >> >> Researchers at Kumamoto University, led by Associate Professor Shingo >> Ito, have now developed a promising drug delivery strategy designed to >> overcome these obstacles. Their approach uses a cyclic peptide that can >> pass through the small intestine. The molecule, called the DNP peptide, >> helps insulin move across the intestinal barrier and into the body after >> oral administration. >> >> Two Complementary Strategies for Oral Delivery >> >> The researchers established two effective approaches to facilitate the >> intestinal absorption of insulin: >> >> Mixing method (interaction-based): In this approach, a modified “D-DNP-V >> peptide” was mixed with zinc-stabilized insulin hexamers. When given orally >> in several diabetes models, including chemically induced (STZ mice) and >> genetic (Kuma mice) models, the treatment quickly lowered blood glucose >> levels to the normal range. With once-daily dosing, stable glycemic control >> was maintained for three straight days. >> >> Conjugation method (covalent-based): In the second approach, the team >> used click chemistry to directly attach the DNP peptide to insulin, >> creating a “DNP–insulin conjugate.” This version produced glucose-lowering >> effects similar to those seen with the mixing method, supporting the idea >> that the peptide actively drives intestinal transport of insulin. >> >> Overcoming the Dose Barrier >> >> One of the biggest challenges in developing oral insulin has been the >> need for very large doses, often more than ten times the amount used in an >> injection. In contrast, this platform reached a pharmacological >> bioavailability of about 33–41% compared with subcutaneous injection. >> >> That finding suggests a major reduction in the amount of insulin required >> for oral use and represents an important step toward real-world clinical >> application. >> >> DNP Peptide Based Delivery Platform May Support Future Oral Insulin >> Development >> >> Engineered DNP peptides—either fused to insulin-binding peptides or >> covalently linked to insulin using click chemistry—directly enhanced >> insulin absorption in mice. These findings demonstrate that DNP peptides >> are versatile carriers for the oral delivery of macromolecular drugs, >> offering a practical way to convert injectable biopharmaceuticals into >> patient-friendly oral medicines. Credit: Chikamatsu et al. >> >> Perspective >> >> “Insulin injections remain a daily burden for many patients,” said >> Associate Professor Shingo Ito. “Our peptide-based platform offers a new >> route to deliver insulin orally and may be applicable to long-acting >> insulin formulations and other injectable biologics.” >> >> The findings were published in the international journal Molecular >> Pharmaceutics. >> >> The research team is now moving forward with translational studies. >> Planned work includes testing the system in large animal models and >> evaluating its performance in human intestinal systems. >> >> Reference: “Small Intestine-Permeable Cyclic Peptide-Based Technology >> Enables Efficient Oral Delivery and Glycemic Efficacy of Zinc-Stabilized >> Insulin Hexamer and Its Analogs in Diabetic Mice” by Shoma Chikamatsu, >> Kosei Sakaguchi, Masataka Michigami, Kimi Araki, Shoen Kume, Midori >> Tokuyasu, Takeshi Masuda, Ikuo Fujii, Sumio Ohtsuki and Shingo Ito, 24 >> November 2025, Molecular Pharmaceutics. >> >> KR IRS 19326 >> > -- You received this message because you are subscribed to the Google Groups "Thatha_Patty" group. To unsubscribe from this group and stop receiving emails from it, send an email to [email protected]. To view this discussion visit https://groups.google.com/d/msgid/thatha_patty/CAL5XZopajyGp7r%2BydehMnWPVGb6-VjTe0Vr-TuruPVKW4kJ0Zg%40mail.gmail.com.
